These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23977426)

  • 41. Aspects on the survival of patients with glioblastoma and the origin and histology of oligodendrogliomas.
    Linz U
    Nat Rev Cancer; 2003 Jul; 3(7):doi:10.1038/nrc1121-c1. PubMed ID: 19006840
    [No Abstract]   [Full Text] [Related]  

  • 42. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.
    Schuessler A; Smith C; Beagley L; Boyle GM; Rehan S; Matthews K; Jones L; Crough T; Dasari V; Klein K; Smalley A; Alexander H; Walker DG; Khanna R
    Cancer Res; 2014 Jul; 74(13):3466-76. PubMed ID: 24795429
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
    Choi BD; Maus MV; June CH; Sampson JH
    Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glioblastoma Therapy in the Age of Molecular Medicine.
    Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS
    Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting role of glioma stem cells for glioblastoma multiforme.
    Zhang X; Zhang W; Mao XG; Zhen HN; Cao WD; Hu SJ
    Curr Med Chem; 2013; 20(15):1974-84. PubMed ID: 23317162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Central nervous system.
    Adamson DC; Rasheed BA; McLendon RE; Bigner DD
    Cancer Biomark; 2010; 9(1-6):193-210. PubMed ID: 22112477
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
    Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
    Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
    Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
    Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
    Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glioma stem cells: their role in chemoresistance.
    Yamada R; Nakano I
    World Neurosurg; 2012 Feb; 77(2):237-40. PubMed ID: 22501017
    [No Abstract]   [Full Text] [Related]  

  • 54. Chimeric antigen receptor T-cell therapy for glioblastoma.
    Rodriguez A; Brown C; Badie B
    Transl Res; 2017 Sep; 187():93-102. PubMed ID: 28755873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
    Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
    Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration.
    Burgoyne AM; Phillips-Mason PJ; Burden-Gulley SM; Robinson S; Sloan AE; Miller RH; Brady-Kalnay SM
    Cancer Res; 2009 Sep; 69(17):6960-8. PubMed ID: 19690139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glioblastoma Multiforme: The Genetic Perspective of the Treatment Planning.
    Kalkan R
    Crit Rev Eukaryot Gene Expr; 2015; 25(4):281-5. PubMed ID: 26559087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features.
    Kim HJ; Kim DY
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33053763
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overview of cellular immunotherapy for patients with glioblastoma.
    Vauleon E; Avril T; Collet B; Mosser J; Quillien V
    Clin Dev Immunol; 2010; 2010():. PubMed ID: 20953324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transcriptomic and Proteomic Data Integration and Two-Dimensional Molecular Maps with Regulatory and Functional Linkages: Application to Cell Proliferation and Invasion Networks in Glioblastoma.
    Gupta MK; Jayaram S; Reddy DN; Polisetty RV; Sirdeshmukh R
    J Proteome Res; 2015 Dec; 14(12):5017-27. PubMed ID: 26464075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.